Cargando…

Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease

Primary focal segmental glomerulosclerosis (FSGS), along with minimal change disease (MCD), are diseases with primary podocyte damage that are clinically manifested by the nephrotic syndrome. The pathogenesis of these podocytopathies is still unknown, and therefore, the search for biomarkers of thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chebotareva, Natalia V., Vinogradov, Anatoliy, Brzhozovskiy, Alexander G., Kashirina, Daria N., Indeykina, Maria I., Bugrova, Anna E., Lebedeva, Marina, Moiseev, Sergey, Nikolaev, Evgeny N., Kononikhin, Alexey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604469/
https://www.ncbi.nlm.nih.gov/pubmed/36293475
http://dx.doi.org/10.3390/ijms232012607
_version_ 1784817821892476928
author Chebotareva, Natalia V.
Vinogradov, Anatoliy
Brzhozovskiy, Alexander G.
Kashirina, Daria N.
Indeykina, Maria I.
Bugrova, Anna E.
Lebedeva, Marina
Moiseev, Sergey
Nikolaev, Evgeny N.
Kononikhin, Alexey S.
author_facet Chebotareva, Natalia V.
Vinogradov, Anatoliy
Brzhozovskiy, Alexander G.
Kashirina, Daria N.
Indeykina, Maria I.
Bugrova, Anna E.
Lebedeva, Marina
Moiseev, Sergey
Nikolaev, Evgeny N.
Kononikhin, Alexey S.
author_sort Chebotareva, Natalia V.
collection PubMed
description Primary focal segmental glomerulosclerosis (FSGS), along with minimal change disease (MCD), are diseases with primary podocyte damage that are clinically manifested by the nephrotic syndrome. The pathogenesis of these podocytopathies is still unknown, and therefore, the search for biomarkers of these diseases is ongoing. Our aim was to determine of the proteomic profile of urine from patients with FSGS and MCD. Patients with a confirmed diagnosis of FSGS (n = 30) and MCD (n = 9) were recruited for the study. For a comprehensive assessment of the severity of FSGS a special index was introduced, which was calculated as follows: the first score was assigned depending on the level of eGFR, the second score—depending on the proteinuria level, the third score—resistance to steroid therapy. Patients with the sum of these scores of less than 3 were included in group 1, with 3 or more—in group 2. The urinary proteome was analyzed using liquid chromatography/mass spectrometry. The proteome profiles of patients with severe progressive FSGS from group 2, mild FSGS from group 1 and MCD were compared. Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups. Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the two group pairs and 14 proteins were validated for both comparisons. In addition, all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. Patients from the FSGS group 2 showed a significantly different profile from both FSGS group 1 and MCD. Among the 47 significantly differentiating proteins, the most significant were apolipoprotein A-IV, hemopexin, vitronectin, gelsolin, components of the complement system (C4b, factors B and I), retinol- and vitamin D-binding proteins. Patients with mild form of FSGS and MCD showed lower levels of Cystatin C, gelsolin and complement factor I.
format Online
Article
Text
id pubmed-9604469
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96044692022-10-27 Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease Chebotareva, Natalia V. Vinogradov, Anatoliy Brzhozovskiy, Alexander G. Kashirina, Daria N. Indeykina, Maria I. Bugrova, Anna E. Lebedeva, Marina Moiseev, Sergey Nikolaev, Evgeny N. Kononikhin, Alexey S. Int J Mol Sci Article Primary focal segmental glomerulosclerosis (FSGS), along with minimal change disease (MCD), are diseases with primary podocyte damage that are clinically manifested by the nephrotic syndrome. The pathogenesis of these podocytopathies is still unknown, and therefore, the search for biomarkers of these diseases is ongoing. Our aim was to determine of the proteomic profile of urine from patients with FSGS and MCD. Patients with a confirmed diagnosis of FSGS (n = 30) and MCD (n = 9) were recruited for the study. For a comprehensive assessment of the severity of FSGS a special index was introduced, which was calculated as follows: the first score was assigned depending on the level of eGFR, the second score—depending on the proteinuria level, the third score—resistance to steroid therapy. Patients with the sum of these scores of less than 3 were included in group 1, with 3 or more—in group 2. The urinary proteome was analyzed using liquid chromatography/mass spectrometry. The proteome profiles of patients with severe progressive FSGS from group 2, mild FSGS from group 1 and MCD were compared. Results of the label free analysis were validated using targeted LC-MS based on multiple reaction monitoring (MRM) with stable isotope labelled peptide standards (SIS) available for 47 of the 76 proteins identified as differentiating between at least one pair of groups. Quantitative MRM SIS validation measurements for these 47 proteins revealed 22 proteins with significant differences between at least one of the two group pairs and 14 proteins were validated for both comparisons. In addition, all of the 22 proteins validated by MRM SIS analysis showed the same direction of change as at the discovery stage with label-free LC-MS analysis, i.e., up or down regulation in MCD and FSGS1 against FSGS2. Patients from the FSGS group 2 showed a significantly different profile from both FSGS group 1 and MCD. Among the 47 significantly differentiating proteins, the most significant were apolipoprotein A-IV, hemopexin, vitronectin, gelsolin, components of the complement system (C4b, factors B and I), retinol- and vitamin D-binding proteins. Patients with mild form of FSGS and MCD showed lower levels of Cystatin C, gelsolin and complement factor I. MDPI 2022-10-20 /pmc/articles/PMC9604469/ /pubmed/36293475 http://dx.doi.org/10.3390/ijms232012607 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chebotareva, Natalia V.
Vinogradov, Anatoliy
Brzhozovskiy, Alexander G.
Kashirina, Daria N.
Indeykina, Maria I.
Bugrova, Anna E.
Lebedeva, Marina
Moiseev, Sergey
Nikolaev, Evgeny N.
Kononikhin, Alexey S.
Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
title Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
title_full Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
title_fullStr Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
title_full_unstemmed Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
title_short Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease
title_sort potential urine proteomic biomarkers for focal segmental glomerulosclerosis and minimal change disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604469/
https://www.ncbi.nlm.nih.gov/pubmed/36293475
http://dx.doi.org/10.3390/ijms232012607
work_keys_str_mv AT chebotarevanataliav potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT vinogradovanatoliy potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT brzhozovskiyalexanderg potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT kashirinadarian potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT indeykinamariai potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT bugrovaannae potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT lebedevamarina potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT moiseevsergey potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT nikolaevevgenyn potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease
AT kononikhinalexeys potentialurineproteomicbiomarkersforfocalsegmentalglomerulosclerosisandminimalchangedisease